Ind-Swift Laboratories Ltd.

As of June 30, 2026, Ind-Swift Laboratories Ltd. carries a market capitalization of 17.67B, placing it among publicly traded companies globally. Its enterprise value stands at 17.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Ind-Swift Laboratories Ltd. has 86.84M shares outstanding.

As of June 30, 2026, Ind-Swift Laboratories Ltd. trades at a trailing price-to-earnings ratio of 29.45.

As of June 30, 2026, Ind-Swift Laboratories Ltd. trades at an EV/EBITDA multiple of 36.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 104.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.67B versus a market cap of 17.67B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.05M in revenue per employee across its workforce of 1,317.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Ind-Swift Laboratories Ltd. recorded 140.15M in income tax expense. That works out to an effective tax rate of 19.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 712.55M, leaving 573.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ind-Swift Laboratories Ltd.'s stock has gained approximately 229.28% over the past 52 weeks. The 50-day moving average sits at 363.12, while the 200-day moving average is 206.90.

Over the twelve months ended June 30, 2026, Ind-Swift Laboratories Ltd. generated 6.65B in revenue and converted that into 573.25M in net income, yielding earnings per share of 6.74. EBITDA reached 484.13M, while operating income came in at 281.43M.

Over the twelve months ended June 30, 2026, Ind-Swift Laboratories Ltd. posted a gross margin of 56.72, reflecting its pricing power and cost economics. The operating margin of 4.23 and net profit margin of 8.62 provide insight into operational efficiency.